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TREK-1 channel activity is a critical regulator of neuronal, cardiac, and smooth muscle
physiology and pathology. The antidepressant peptide, spadin, has been proposed to be
a TREK-1-specific blocker. Here we sought to examine the mechanism of action
underlying spadin inhibition of TREK-1 channels. Heterologous expression in Xenopus
laevis oocytes and electrophysiological analysis using two-electrode voltage clamp in
standard bath solutions was used to characterize the pharmacological profile of wild-type
and mutant murine TREK-1 and TREK-2 channels using previously established human
K2P activators; arachidonic acid (AA), cis-4,7,10,13,16,19-docosahexaenoic acid (DHA),
BL-1249, and cinnamyl-3,4-dihydroxy-a-cyanocinnamate (CDC) and inhibitors; spadin
and barium (Ba2+). Mouse TREK-1 and TREK-2 channel currents were both significantly
increased by AA, BL-1249, and CDC, similar to their human homologs. Under basal
conditions, both TREK-1 and TREK-2 currents were insensitive to application of spadin,
but could be blocked by Ba2+. Spadin did not significantly inhibit either TREK-1 or TREK-2
currents either chemically activated by AA, BL-1249, or CDC, or structurally activated via a
gating mutation. However, pre-exposure to spadin significantly perturbed the subsequent
activation of TREK-1 currents by AA, but not TREK-2. Furthermore, spadin was unable to
prevent activation of TREK-1 by BL-1249, CDC, or the related bioactive lipid, DHA.
Spadin specifically antagonizes the activation of TREK-1 channels by AA, likely via an
allosteric mechanism. Lack of intrinsic activity may explain the absence of clinical side
effects during antidepressant therapy.
Keywords: spadin, TREK-1, TREK-2, antagonism, arachidonic acidINTRODUCTION
Two-pore domain (K2P) channels generate a background or leak potassium (K
+) ion conductance
critical to the control of cell membrane potential and excitability (Goldstein et al., 2001; Feliciangeli
et al., 2015). Fifteen mammalian genes (KCNK) encode K2P subunits containing four
transmembrane domains (TM1-4) flanking two pore-forming domains (P1, P2), that associateAbbreviations: 4-AP, 4-aminopyridine; AA, arachidonic acid; CDC, cinnamyl-3,4-dihydroxy-a-cyanocinnamate; DHA, cis-
4,7,10,13,16,19-Docosahexaenoic acid; GI, gastrointestinal; FFA, flufenamic acid; TEA, tetraethylammonium.
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membrane proteins (Renigunta et al., 2015). TWIK-related K+
channels (TREK-1, TREK-2, and TRAAK) are a mechano-gated
subclass of K2P channels, and are highly expressed throughout
the nervous system (Talley et al., 2001) as well as in several non-
neuronal tissues including cardiac and smooth muscles (Gurney
and Manoury, 2009; Schmidt et al., 2014; Ma et al., 2018).
TREK-1 in particular plays a central role in pain perception,
neuroprotection, and cardiac rhythmogenesis (Alloui et al.,
2006; Wiedmann et al., 2016; Lamas and Fernandez-
Fernandez, 2019) and is considered a viable therapeutic target
for treating depression (Heurteaux et al., 2006), atrial fibrillation
(Lugenbiel et al., 2017), and hypermotility disorders of the
gastrointestinal tract (Ma et al., 2018).
Gating of TREK channels is polymodal, and open
probab i l i t y can be de t e rmined by a p l e thora o f
physiochemical signals including pH, mechanical stretch,
temperature, and bioactive lipids (Noel et al., 2011).
Specifically, TREK-1 and TREK-2 channels can be strongly
and reversibly activated by polyunsaturated free fatty acids
(PUFAs) such as AA and DHA through a mechanism involving
the C-terminal domain (Fink et al., 1998; Patel et al., 1998;
Maingret et al., 1999; Ferroni et al., 2003). Other activators
including caffeic acid esters [such as cinnamyl-3,4-dihydroxy-
a-cyanocinnamate (CDC)] and cyclooxygenase inhibitors
including BL-1249 and FFA (Danthi et al., 2004; Veale et al.,
2014) work independently of the C-terminal domain and are
thought to bind below the selectivity filter to open the filter gate
(Schewe et al., 2019). Conversely, there is a surprising paucity
of TREK channel blockers that have the potential to be
exploited for therapeutic purposes. TREK channels are not
sensitive to classical potassium channel blockers like TEA, 4-
AP, and cesium ions (Cs+) (Fink et al., 1996; Koh et al., 2001;
Cadaveira-Mosquera et al., 2011), but can be inhibited by
barium ions (Ba2+) with an IC50 ~1 mM (Ma et al., 2011).
TREK-1 channels are also sensitive to selective serotonin
reuptake inhibitors (SSRIs) such as fluoxetine (Kennard et al.,
2005) which are thought to bind within intramembrane
fenestrations in a state-dependent manner (Dong et al., 2015;
Mcclenaghan et al., 2016).
Recently a TREK-1 specific inhibitor with therapeutic
potential to treat depression was identified (Mazella et al.,
2010; Moha Ou Maati et al., 2012). Spadin is an engineered
fragment of a natural NTSR3/sortilin propeptide released into
blood after the cleavage of prosortilin by the protein convertase,
furin. Spadin binds with high affinity to the neurotensin (NT)
receptor which has been shown to physically associate with the
TREK-1 channel, regulating its cell surface expression (Mazella
et al., 2010). Spadin has also been shown biochemically to bind to
TREK-1, and suggested to inhibit channel currents but only
when pre-activated with AA (Mazella et al., 2010), indicating
state-dependent association. Here, using murine forms of TREK-
1 and TREK-2 heterologously expressed in Xenopus oocytes, we
sought to understand the mechanism of spadin inhibition of
TREK-1 channel currents.Frontiers in Pharmacology | www.frontiersin.org 2MATERIALS AND METHODS
Molecular Biology
Mouse TREK-1 (mTREK-1) and mouse TREK-2 (mTREK-2)
were a kind gift from Guillaume Sandoz (Université de Nice
Sophia Antipolis), while human TREK-1 (hTREK-1) was kindly
provided by Dierk Thomas (University of Heidelberg). Plasmid
DNA was isolated using the Qiagen Miniprep Kit (Qiagen,
Valencia, CA), and all constructs were sequenced by Eurofins
Genomics (Ebersberg, Germany). All plasmid DNA were sub-
cloned into our in-house pMAX expression vector (based on
pcDNA3.1), linearized with PacI (New England Biolabs), and
purified using a QIAquick PCR Purification Kit (Qiagen,
Valencia, CA). Site-directed mutagenesis was performed by
PCR. cRNA transcripts were generated by in-vitro
transcription using the T7 mMESSAGE mMACHINE kit
(Ambion, Inc., Austin, TX). cRNA concentration and purity
was determined by spectrophotometry and visualized for
qualitative analysis by gel electrophoresis.
Oocyte Preparation and RNA Injection
Xenopus laevis ovaries were sourced from the European Xenopus
Resource Centre (University of Portsmouth, Portsmouth, UK).
Experiments were approved by the Animal Welfare and Ethics
Review Committee of the University of Portsmouth, and were
performed in accordance with the Animals (Scientific Procedures)
Act 1986 (UK). Stage IV–V oocytes were isolated and
defolliculated in Ca2+-free OR-2 solution (in mM: 82.5 NaCl, 2.5
KCl, 1 MgCl2, 10 HEPES, pH 7.4 tris-base) using a combination of
manual dissection and collagenase treatment (~1 h in 2 mg/ml
Worthington type II collagenase, Lorne Labs, UK). Oocytes were
injected with cRNA (2–10 ng) and incubated at 16°C in ND-96
solution (in mM: 96 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 10 HEPES,
pH 7.6, tris-base) containing 50 µg/ml gentamycin and 1%
penicillin/streptomycin, for at least 24 h before analysis.
Electrophysiology
Whole-cell currents in oocytes were recorded 1–3 days post-
injection by two-electrode voltage clamp (TEVC) using aWarner
TEV700 oocyte clamp amplifier (Harvard Apparatus, UK) and
Axon Digidata 1440A (Molecular Devices, UK). Microelectrodes
were back filled with 3 M KCl and had tip resistances of 0.2–1.0
MW. Currents were recorded at room temperature (21 ± 1°C)
with constant solution flow at 1–2 ml/min with bath solution
containing (in mM): 96 NaCl, 4 KCl, 1 MgCl2, 0.3 CaCl2, 10
HEPES (pH 7.6, tris-base). Data were sampled at 5 kHz, filtered
at 1 kHz and recorded using Clampex 10.1 software (Axon
Instruments, Inc.). Currents were not adjusted for leak or
capacitance. Oocyte membrane potential was held at −80 mV
and step depolarized to potentials ranging from −120 mV to +60
mV in 10 mV steps for a duration of 500 ms.
Data and Statistical Analysis
The raw data supporting the conclusions of this manuscript will
be made available by the authors, without undue reservation, toApril 2020 | Volume 11 | Article 434
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(Axon Instruments, Inc.) and tabulated in Excel (Microsoft
Office 2013). Current-voltage (I-V) relationships were
generated from steady-state currents at potentials between
−120 mV and +60 mV. Statistical analyses and graphical
evaluations were performed with Prism 7.0 (GraphPad, Inc., La
Jolla, CA, USA). For all analysis, n values represent oocytes
numbers. All data are presented as the arithmetic mean ± SEM
unless stated otherwise. Statistical comparisons were made using
either Student's paired t test or one-way ANOVA (not repeated
measures). A p < 0.05 was considered statistically significant.
Drugs
Arachidonic acid (AA), BL-1249, CDC, cis-4,7,10,13,16,19-
docosahexaenoic acid (DHA), and barium chloride (BaCl2)
were purchased from Sigma-Aldrich, spadin was bought from
Tocris. All substances, except BaCl2, were stored as stocks (1
mM–1 M) at −20°C and diluted to the required concentrations in
standard bath solution immediately prior to experimentation.RESULTS
Mouse TREK-1 and TREK-2 Channels Are
Biophysically and Pharmacologically
Comparable to Their Human Counterparts
In order to allow a direct comparison to previous work by
ourselves and others using mouse model tissue, we conducted
a comprehensive biophysical and pharmacological assessment of
cloned mouse TREK-1 and TREK-2 channels by two-electrode
voltage clamp after heterologous expression in X. laevis oocytes.
Robust ionic currents were recorded in standard bath solution
containing 4 mM K+ from both mTREK-1 (Figure 1A) and
mTREK-2 (Figure 1D) expressing oocytes. Such significant
currents were absent in water-injected oocytes. The phenotype
of the two channel currents resembled that of their well-
characterized human K2P channel counterparts; quasi time-
independent activation and strong outwardly rectifying
currents in physiological solutions with minimal inward
currents observed in 4 mM K+ (Figures 1B, E).
When external K+ concentration ([K+]o) was increased to 140
mM K+, prominent inward currents were revealed for both
channels at voltages below the predicted equilibrium potential
(EK = 0 mV, Figures 1B, E). Incremental increases in
extracellular K+ concentration from 4 mM to 140 mM induced
a parallel shift in the voltage threshold at which outward ionic
currents were observed (EREV). A plot of EREV as a function of
[K+]o revealed slopes of 47.3 ± 2.2 mV (Figure 1C, mTREK-1)
and 49.4 ± 0.4 mV (Figure 1F, mTREK-2) close to the calculated
Nernst value of 58.2 mV indicating these two channels are highly
selective for K+ ions.
Previous studies have established that human TREK channel
currents are sensitive to a wide range of pharmacological agents,
including activation by structurally diverse compounds such as
AA (Fink et al., 1998; Patel et al., 1998; Lesage et al., 2000), BL-Frontiers in Pharmacology | www.frontiersin.org 31249 (Veale et al., 2014), and CDC (Danthi et al., 2004), the
structures of which are shown in Figure 1G.
Analysis of mTREK-1 currents at recorded at 0 mV revealed a
significant increase in current magnitude upon application of 10
mM AA (256.8 ± 6.7%), 1 mM BL-1249 (392.9 ± 29.5%), and 10
mM CDC (307.8 ± 10.1%) respectively (Figure 1H). Application
of 1 mM Ba2+ caused a significant reduction of mTREK-1
currents to 56.1 ± 1.4% at 0 mV compared to control
(Figure 1H).
Similar activation and inhibition was seen in mTREK-2
channels. mTREK-2 currents recorded at 0 mV were
significantly increased by application of 10 mM AA (265.77 ±
6.5%), 3 mM BL-1249 (333.7 ± 19.3%), and 10 mM CDC (307.8 ±
10.1%) respectively (Figure 1I). Similar to mTREK-1, mTREK-2
currents recorded at 0 mV were significantly inhibited in the
presence of 1 mM Ba2+ to 55.5 ± 3.4% (Figure 1I). These results
reveal that murine TREK-1 and TREK-2 channels possess a
similar pharmacological profile as their human counterparts;
activation by AA, BL-1249, and CDC, and inhibition by barium.
Spadin Specifically Antagonizes AA-
Activation of TREK-1 Channels
Spadin has previously been suggested to be a specific blocker of
TREK-1 channels, acting via a direct channel interaction, with an
IC50 of ~70 nM at 0 mV after pre-activation by AA (Mazella
et al., 2010). Here, mTREK-1 channels pre-activated with 10 mM
AA were unable to be significantly inhibited by 1 mM spadin
(Figures 2A, B), a concentration predicted to induce ~75%
inhibition (Mazella et al., 2010). At 0 mV, mean AA-activated
current mTREK-1 current was 1.9 ± 0.1 mA compared to 2.1 ±
0.1 mA following the addition of spadin. Furthermore, mTREK-1
basal channel activity was also insensitive to spadin, with channel
currents at 0 mV measured as 1.4 ± 0.1 mA (control mTREK-1
current) versus 1.5 ± 0.1 mA (1 mM spadin) (Figures 2C, D).
Given that spadin did not appear to be a traditional blocker of
mTREK-1 channels, we decided to investigate whether spadin could
antagonize AA-activation of mTREK-1 channels. Oocytes were
incubated for 3–5 min in bath solution containing 1 mM spadin
before addition of 10 mM AA (time-course shown in Figure 2C).
Pre-application of 1 mM spadin significantly perturbed the
activation of mTREK-1 channels by AA by 52.2 ± 14.7%, when
compared to AA-activated currents after the removal of spadin
(Figures 2C, D). This was not a species-specific phenomenon.
Spadin was also unable to block AA-activated currents generated by
human TREK-1, and induced comparable antagonism of AA-
activation of hTREK-1 currents (Supplementary Figure 1).
In order to begin to understand the mechanism of action of
spadin, we next wanted to assess the antagonistic activity of
spadin against other known TREK-1 activators. Spadin was
unable to prevent BL-1249 (1 mM) stimulation of mTREK-1
currents at 0 mV; 3.3 ± 0.2 mA versus 3.5 ± 0.2 mA in the presence
and absence respectively of spadin (Figure 2E), Similarly spadin
was unable to prevent CDC (10 mM) stimulation of mTREK-1
currents at 0 mV; 3.4 ± 0.1 mA versus 3.7 ± 0.2 mA in the presence
and absence respectively of spadin (Figure 2F).April 2020 | Volume 11 | Article 434
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AA, known to activate TREK-1 channels (Patel et al., 2001).
Application of 10 mM DHA, as expected, exhibited a significant
enhancement of mTREK-1 currents, with an increase of 2.3 ±
0.2-fold at 0 mV compared to control (Figure 2G). Spadin was
unable to block the DHA-activated mTREK-1 currents [Figure
2G; 2.6 ± 0.2 mA (DHA activated current) versus 2.9 ± 0.3 mA
(DHA activated current + spadin]. Moreover, spadin was unable
to prevent DHA stimulation of mTREK-1 currents; 3.0 ± 0.3 mA
versus 3.3 ± 0.2 mA in the presence and absence respectively of
spadin (Figure 2H).Frontiers in Pharmacology | www.frontiersin.org 4Spadin Does Not Antagonize AA-
Activation of mTREK-2 Channels
Given the effects of spadin on human and mouse TREK-1
channels, and the close biophysical phenotypes of TREK-1 and
TREK-2, the effects of spadin were tested on mTREK-2 channels
expressed in X. laevis oocytes, and assayed using TEVC. Figure
3A shows that 1 mM spadin was unable to block mTREK-2
channels pre-activated by 10 mMAA; currents measured at 0 mV
were 3.1 ± 0.1 mA and 3.3 ± 0.1 mA in the absence or presence of
spadin, respectively (Figure 3B). Comparable to observations
with TREK-1, spadin alone failed to inhibit basal mTREK-2A B C
D
G
H I
E F
FIGURE 1 | Mouse TREK-1 and TREK-2 channels are biophysically and pharmacologically comparable to their human counterparts. Exemplar current traces of
mTREK-1 (A) and mTREK-2 (D) elicited by voltage pulses from −120 to +60 mV in 10 mV steps, for 500 ms from a holding potential of −80 mV (inset), in both
asymmetric K+ solutions (4 mM) or symmetric K+ solutions (140 mM). In each panel, scale bars represent 2 mA and 100 ms. The zero current level is indicated by red
dashed line. (B, E) Mean current-voltage (I-V) relationships taken from steady-state currents in bath solution containing low (asymmetric) K+ (4 mM, black squares) or
high (symmetric) K+ (140 mM, open squares) for (B) mTREK-1 (n = 7) and (E) mTREK-2 (n = 8). (C, F) Reversal potential (EREV) plotted as a function of [K
+]o (mean ±
SEM) for (C) mTREK-1 and (F) mTREK-2 currents. Data points are fitted with a linear relationship (red line). Dashed line represents Nernstian theoretical linear
relationship of equilibrium potential for K+ (EK) with changing [K
+]o as calculated using the Nernst equation, assuming [K
+]i of 140 mM (slope = −58.2 mV). (G)
Chemical structures of three main activators of TREK channels. (H, I) Bar graphs showing effects on mean (± SEM) normalized mTREK-1 (H) and mTREK-2 (I)
currents measured at 0 mV (in %) after application of either 10 mM AA, 1 mM BL-1249 (mTREK-1), 3 mM BL-1249 (mTREK-2), 10 mM CDC, or 1 mM Ba2+. Dashed
line indicates control current level. All data represents n > 6 oocytes. ***p < 0.001, ****p < 0.0001, Student's paired t-test conducted on raw data.April 2020 | Volume 11 | Article 434
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(Figures 3C, D). Furthermore, the antagonistic effect of spadin
observed on AA-activation in TREK-1 channels was absent in
mTREK-2 channels (Figure 3C). Pre-application of 1 mM spadin
showed a small but insignificant antagonization of AA activation
of mTREK-2 at 0 mV (Figure 3D).
Comparable to mTREK-1, spadin was unable to prevent BL-
1249 (3 mM) stimulation of mTREK-2 currents at 0 mV (Figure
3E, 2.8 ± 0.1 mA versus 2.9 ± 0.2 mA in the presence and absence
respectively of spadin), or CDC (10 mM) stimulation of mTREK-
1 currents at 0 mV (Figure 3F, 2.8 ± 0.2 mA versus 3.1 ± 0.3 mA
in the presence and absence respectively of spadin).Frontiers in Pharmacology | www.frontiersin.org 5Ba2+ Blocks AA and BL-1249 Activated
mTREK-1 and mTREK-2 Channels
Given the absence of spadin inhibition on AA-activated TREK-1
currents, we tested the ability of the classical potassium channel
pore blocker, barium (Ba2+), to inhibit pre-activated mTREK-1
and mTREK-2 currents. As expected, AA-activated mTREK-1
currents measured at 0 mV showed significant block by 1 mM
Ba2+ by 46.2 ± 5.3% (2.2 ± 0.1 mA versus 1.23 ± 0.1 mA, Figure
4A). Likewise, BL-1249 pre-activated mTREK-1 currents were
also inhibited by 39.1 ± 3.0% (2.6 ± 0.1 mA versus 1.6 ± 0.1 mA,
Figure 4C). This degree of inhibition by barium is close to the
50% block of TREK-1 currents observed in a previous study withA B
C D
E F
G H
FIGURE 2 | Spadin specifically antagonizes AA-activation of TREK-1 channels. (A, C) Exemplar time-courses of mTREK-1 currents measured at 0 mV recorded
from oocytes by TEVC, under different bath conditions; control (4K, black), 1 mM spadin alone (Sp, red), 10 mM AA alone (AA, green), or 1 mM spadin plus 10 mM AA
(Sp +AA, white) as indicated on bar. (B, D) Mean current-voltage relationships of experiments from A and C respectively (n = 8–12). Numbers in brackets refer to the
order of application of compounds, mirroring respective time-courses. (E, F) Mean bar graphs showing the effect of spadin on mTREK-1 current activation by (E)
BL-1249 and (F) CDC. mTREK-1 current amplitudes were recorded at 0 mV by TEVC in control bath conditions (4K, black), and following pre-treatment with 1 mM
spadin alone (red), 1 mM spadin plus indicated activator (white) and activators alone; 1 mM BL-1249 (orange) or 10 mM CDC (blue). (G, H) Mean bar graphs showing
the effect of spadin on mTREK-1 currents amplitudes recorded at 0 mV by TEVC in the presence of DHA. (G) Mean mTREK-1 currents recorded in control bath
conditions (4K, black), and following pre-activation with 10 mM DHA (green) and when supplemented with 1 mM spadin (white). (H) Mean mTREK-1 currents
recorded in control bath conditions (4K, black), and following pre-treatment with 1 mM spadin alone (red), supplementation with 10 mM DHA (white) or 10 uM DHA
alone (green). Data are presented as mean ± SEM, n = 10 for both. n.s, not significant (p > 0.05), ****p < 0.0001, one-way ANOVA followed by Tukey's multiple
comparisons test.April 2020 | Volume 11 | Article 434
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observed at 0 mV in mTREK-2 channels pre-activated with
either AA (37.2 ± 5.5%; 2.8 ± 0.1 mA versus 1.8 ± 0.1 mA,
Figure 4B) or BL-1249 (35.5 ± 4.2%; 2.1 ± 0.2 mA versus 1.3 ± 0.1
mA, Figure 4D).
Spadin Does Not Block Structurally
Activated mTREK-1 Channels
Taken together, these findings led us to posit that spadin may
antagonize the activation of TREK-1 channels by AA by
interfering with the postulated gating transition from the
“down” to the “up” state of the TREK-1 filter, via a
mechanism similar to that proposed for the action of the
blocker norfluoxetine on the TREK-2 channel (Dong et al.,
2015). We therefore introduced a mutation into the mTREK-1
channel (mTREK-1-Y284A) analogous to the mutation
previously described in TREK-2 (Figure 5A) which had beenFrontiers in Pharmacology | www.frontiersin.org 6demonstrated to significantly reduce norfluoxetine block
(Mcclenaghan et al., 2016). This mutation promotes a
conformation of pore-lining helices in the “up” state, creating a
hyper-active channel. If spadin blocks activated TREK-1
channels as previously suggested, this mutant channel might be
expected to be spadin-sensitive.
As anticipated, current magnitude of mTREK-1-Y284A
mutant channels was enormous (~10 mA at 0 mV), even when
cRNA was serially diluted before injection. Furthermore, mutant
channels were no longer sensitive to AA activation; 10.4 ± 2.3 mA
(control) versus 10.4 ± 2.4 mA (AA) (Figure 5B), indicating a
high baseline open probability therefore rendering the channels
insensitive to further activation by AA. This prevented the
assessment of antagonistic activity of spadin in the mutant
channel. However, application of 1 mM spadin alone failed to
inhibit mTREK-1-Y284A basal currents; 11.3 ± 1.9 mA (control)
versus 11.3 ± 2.0 mA (spadin) (Figure 5C), and reinforces ourA B
C D
E F
FIGURE 3 | Spadin does not antagonize AA-activation of mTREK-2 channels. (A, C) Exemplar time-courses of mTREK-2 currents measured at 0 mV recorded from
oocytes by TEVC, under different bath conditions; control 4K (black), 1 mM spadin alone (red), 10 mM AA alone (green) or 1 mM spadin plus 10 mM AA (white) as
indicated on bar. (B, D) Mean current-voltage relationships of experiments from A and C respectively (n = 7-9). Numbers in brackets refer to the order of application
of compounds, mirroring respective time-courses. (E, F) Mean bar graphs showing the effect of spadin on mTREK-2 current activation by (E) BL-1249 (F) CDC.
mTREK-2 current amplitudes were recorded at 0 mV by TEVC in control bath conditions (4K, black), and following pre-treatment with 1 mM spadin alone (red), 1 mM
spadin plus indicated activator (white) and activators alone; 3 mM BL-1249 (orange) or 10 mM CDC (blue). Data are presented as mean ± SEM, n = 8-10. n.s, not
significant (p > 0.05), *p < 0.05, ****p < 0.0001, one-way ANOVA followed by Tukey's multiple comparisons test.April 2020 | Volume 11 | Article 434
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B C
FIGURE 5 | Gating mutation in TM4 reveals spadin is unable to inhibit hyper-active mTREK-1 channels. (A) left panel, structural diagram of mTREK-1 showing
position of Y284A gating mutation, right panel, sequence alignment of distal pore-lining transmembrane domains (TM4) of mTREK-1 (NP_034737), hTREK-2
(NP_612191), KCNK0 (AAC69250), (TM6) Shaker (CAA29917), and (TM2) KcsA (POA333.1). Highlighted in bold are the tyrosine residue of mTREK-1 (Y284) and the
analogous tyrosine in hTREK-2 (Y315). Mutation of Y315 to alanine significantly reduces norfluoxetine activity in human TREK-2 (Mcclenaghan et al., 2016). *
Conserved glycine hinge residue (boxed). Mutation to this residue is known to promote stabilization of the open state across the potassium channels listed. (B, C)
Mean bar graphs of chimera channel currents recorded at 0 mV by TEVC in control bath conditions (4K, black), and following treatment with (B) 10 uM AA (n = 9,
green) or (C) 1 mM spadin (n = 7, red). Data are presented as mean ± SEM. p >0.05, not significant (n.s).A B
C D
FIGURE 4 | Ba2+ blocks AA and BL-1249 activated of mTREK-1 and mTREK-2 channels. Bar graphs displaying the effects of barium ion (Ba2+) block of (A) AA-
activated mTREK-1, (B) AA-activated mTREK-2, (C) BL-1249 activated mTREK-1, and (D) BL-1249 activated mTREK-2 channel currents. mTREK-1 and mTREK-2
channel currents were recorded from Xenopus laevis oocytes by TEVC. (A, C) Mean currents for mTREK-1 at 0 mV showing the effects of 1 mM Ba2+ after pre-
activation by 10 mM AA (A, n = 8) or 1 mM BL-1249 (C, n = 10). (B, D) Mean currents for mTREK-2 at 0 mV showing the effects of 1 mM Ba2+ after pre-activation
with 10 mM AA (B, n = 6) or 3 mM BL-1249 (D, n = 9) activation. Data are presented as mean ± SEM. *p < 0.05, **p <0.01, ***p < 0.001, ****P < 0.0001, Student's
paired t-test.Frontiers in Pharmacology | www.frontiersin.org April 2020 | Volume 11 | Article 4347
Ma and Lewis Antagonism of TREK-1 Channels by Spadinsuggestion that spadin is not a channel blocker of activated
channels, but selectively and specifically antagonizes AA-
activation of TREK-1 channels via an allosteric mechanism.DISCUSSION
TREK-1 is a background potassium channel, the protagonist in
multiple key physiological functions and pathophysiological
conditions in nervous and cardiovascular tissue including
neuroprotection, depression, epilepsy, pain, ischemia, and atrial
fibrillation (Djillani et al., 2019). We have previously shown
pharmacological evidence that implicates TREK-1 as a major
potassium conductance regulating gastrointestinal smooth muscle
contractility (Ma et al., 2018), providing a potential therapeutic
target for motility disorders. Although a plethora of physiochemical
activators of TREK channels have been characterized, including
acidic pHi, mechanical stretch, lipids, and compounds including
caffeic acid derivatives and fenamates (Vivier et al., 2016), there is a
surprising paucity of TREK-1 channel blockers that have the
potential to be exploited for therapeutic purposes. Recently
spadin, an engineered fragment of a natural propeptide released
into blood after the cleavage of prosortilin by furin, was identified as
a potent and selective blocker of TREK-1 channels (Mazella et al.,
2010). Spadin activity was shown to require pre-activation of the
TREK-1 channel by AA, indicating state-dependent binding. Here,
using murine forms of TREK-1 and TREK-2, we provide evidence
that spadin is not a direct blocker of TREK-1 when expressed in
heterologous systems but an antagonist, displaying no intrinsic
activity, able to selectively prevent AA-activation of TREK-1
channels through an allosteric mechanism.
Given the inconsistency of our findings with previous studies,
critical comparisons were sought. Spadin, a partial NTSR3/sortilin
propeptide, has been shown biochemically to directly bind to the
TREK-1 channel (note in the absence of AA) and with much higher
affinity to the NT receptor (8 nM) (Mazella et al., 2010). Spadin has
been proposed to induce a mixture of direct channel blocking effects;
inducing a voltage-independent reduction in current (after activation
with AA) with an IC50 of ~60–70 nM, and channel protein
internalization (Mazella et al., 2010). The authors further reveal
that the NT receptor (NTSR3/sortilin) itself physically associates
with the TREK-1 channel regulating its expression and function.
Therefore in those studies utilizing expression systems (COS-7 cells)
or primary tissue known to endogenously express the NT receptor
(NTSR3, gp95/sortilin), it is not clear whether the action of spadin
occurs directly via the channel itself or indirectly through the NT
receptor. Our data using an embryonic heterologous expression
system agree that spadin likely binds directly to the TREK-1 channel
in the absence of AA, independent of its activity through the NT
receptor. When observed in isolation, spadin clearly works as an
antagonist and not as a direct channel blocker. Furthermore, what is
not clear from previous studies is how, given its proposed direct
block of TREK-1 channels, spadin specifically affects depression with
little impact on pain, epileptogenesis or cardiac phenotypes, raising
questions about its mechanism of action. However, an antagonisticFrontiers in Pharmacology | www.frontiersin.org 8mechanism would help explain these findings; no intrinsic activity,
but preventing activation of the TREK-1 channel in those cells and
tissues undergoing specific disease processes.
Our findings agree with those described previously; spadin
has no effect on basal TREK-1 channel currents (Mazella et al.,
2010) and is specific to TREK-1 (Moha Ou Maati et al., 2012).
We show that spadin is unable to inhibit TREK-1 channels
activated both chemically (via AA, BL-1249, or CDC), or by via
structural mutation. Spadin specificity has been argued based on
lack of effect in a TREK-1 knockout (kcnk2−/− mice) (Mazella
et al., 2010). Mechanistically, if spadin induces effects indirectly
through the NT receptor, then removing the coupled effector
protein (TREK-1) would consequently remove the response, and
does not verify a direct channel blocking effect. Furthermore, it
has been suggested that spadin induces internalization of the
TREK-1 channel through its action on NT receptors (Mazella
et al., 2010), a mechanism that is likely responsible for the long-
term clinical impact of spadin seen in vivo. However, given that
ion channel protein turnover at the membrane occurs on a
timescale of hours (Jugloff et al., 2000), this does not explain the
acute effects shown in acute electrophysiological recordings.
Site of Action
We have provided evidence that spadin is specific to TREK-1 and
does not antagonize the closely related TREK-2 channel, in line
with previous reports (Moha Ou Maati et al., 2012). However,
uniquely, spadin antagonism was selective for AA activation, and
had no influence on TREK-1 channel activation by other
chemical activators, BL-1249 or CDC, or the related PUFA,
DHA. A charge cluster in the C-terminal domain of TREK-1
and TREK-2 is considered a crucial site for the activity of
bioactive lipid molecules such as AA and DHA (Patel et al.,
1998; Kim et al., 2001b; Honore et al., 2002). Given that spadin is
a water-soluble peptide, we ruled out an orthosteric mechanism
of antagonism involving the C-terminal domain of TREK-1.
However that spadin antagonizes AA activation of TREK-1
channels, and not that of DHA, suggests that AA activation of
TREK-1 may involve a mechanism distinct from the C-terminal
domain, interacting with other regions in TREK-1 or inducing its
effects through interactions with the lipid bilayer (Meves, 2008).
The related K2P channel, TRAAK, similarly contains a cluster of
charged amino acids in its C-terminal domain, replacement of
which leaves AA sensitivity intact (Kim et al., 2001a).
Spadin did not antagonize the effects of BL-1249 or CDC, ruling
out a mechanism at these binding sites. Schewe et al, have recently
identified the binding site of BL-1249 (and likely CDC), a negatively
charged activator (NCA), to be below the selectivity filter, a
conserved site now thought to convey polypharmacological
properties to chemical activators across different K+ channel
families (Schewe et al., 2019). This also suggests that the
mechanism of activation of TREK-1 channels by AA and NCA's
are different, as spadin selectively antagonizes AA activation, but not
BL-1249 or CDC. Spadin could possibly share a similar binding site
as the water-soluble TREK channel blocker fluoxetine, and its active
metabolite, norfluoxetine. Molecular modeling of TREK-2 inApril 2020 | Volume 11 | Article 434
Ma and Lewis Antagonism of TREK-1 Channels by Spadincomplex with norfluoxetine indicates the inhibitor binds in a pocket
underneath the P2 helix of the selectivity filter at a site that is framed
by the M2, M3, and M4 transmembrane helices (Dong et al., 2015).
However, there is currently no co-crystal structure or molecular
modeling simulations of TREK-1 in complex with spadin.
Mechanism of Action—Allosteric
Antagonism
Our data infers that spadin is able to antagonize AA-activation of
TREK-1 channels via a mechanism that is distinct from the likely
site of AA activity, the C-terminal domain, therefore suggesting an
allosteric mechanism of antagonism. We hypothesize that the
molecular basis of spadin antagonism may be similar to the state-
depending binding of fluoxetine in TREK channels. Crystal
structures of TREK-1 (Lolicato et al., 2017), TREK-2 (Dong
et al., 2015), and TRAAK (Brohawn et al., 2012) channels in the
“up” and “down” conformations have been reported, and suggest
different conformational gating states. The crystal structures of the
hTREK-2 channel in complex with the inhibitor norfluoxetine
suggests that conformational changes induced by drug binding
can modulate channel activity (Dong et al., 2015). Movement of
the pore-lining helices convert the channel between “down” and
“up” functional states. The “down” state represents a closed and
poorly conductive state stabilized by inhibitors such as
norfluoxetine binding within the fenestrations, whereas the “up”
state can be induced by membrane stretch or AA activation and
represents an open and more conductive state (Dong et al., 2015).
Norfluoxetine accesses its binding site only when the TREK-2
channel is in the “down” state. TREK-2 shifts to the “up”
functional state when activated by AA, and becomes resistant to
norfluoxetine (Mcclenaghan et al., 2016). We posit that spadin
works in a similar way; spadin is only able to bind to TREK-1
when the channel is in the “down” state. Binding of spadin
restricts the ability of the channel protein to adopt the “up” state
conformation upon AA activation. Conversely, spadin is unable to
bind when the channel is in the “up” state after pre-activation by
AA, and therefore displays no channel blocking effect.
The inhibitory power of norfluoxetine can been markedly
reduced by the mutation hTREK-2-Y315A (shown in Figure
5B), which promotes a conformation of pore-lining helices in the
“up” state (Mcclenaghan et al., 2016). Indeed, mutation of the
analogous site in TREK-1, Y284A, produces a channel with all
the hallmarks of a channel trapped in the “up” state; very large
steady-state current amplitudes and insensitivity to activation by
AA. Previous studies suggested that spadin is only able to inhibit
channels in the activated state (Mazella et al., 2010), however we
observed no inhibition of current in the constitutively active
mTREK-1-Y284A mutant.
Limitations of the Study
The experimental data presented were derived from the X. laevis
oocyte expression system. Although a well-established and suitable
model system for evaluating the biophysical and pharmacological
properties of ion channels, there is the possibility that findings ofFrontiers in Pharmacology | www.frontiersin.org 9this nature could be inconsistent between different expression
systems and cell types. Furthermore, inconsistencies may arise
from different methods of peptide synthesis.
Taken together these data demonstrated that spadin displays
direct, selective antagonism of AA-activation of TREK-1 channels.
Pharmacological and mutational analysis suggests spadin binds to
TREK-1 in the “down” conformation at a site distinct from the C-
terminal domain, and likely on the extracellular face of the channel
protein. Understanding the molecular nature of spadin antagonism
should assist in the development of future antidepressant
compounds, providing a platform for the design of TREK-1
specific drugs that also lack intrinsic activity. However, further
studies involving molecular modeling or structural analysis through
co-crystallization techniques are required to determine the exact
binding site of spadin on the TREK-1 channel protein, and help
further dissect the underlying molecular mechanism of action of
this clinically relevant antidepressant.DATA AVAILABILITY STATEMENT
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